NervGen Pharma Corp. NGEN 深 沪
等待开盘 05-21 09:30:00 美东时间
3.74
+0.180
+5.06%
华盛通- 最 高3.75
- 今 开3.58
- 成交量 8.01万股
- 最 低 3.58
- 昨 收 3.56
- 总市值 3.03亿
- 52周最高 6.30
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 3.51
- 委 比 -90.43%
- 总股本 8093.09万
- 历史最高 6.30
- 量 比 0.45
- 振 幅 4.78%
- 历史最低 3.51
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported progress on its NVG-291 clinical development, including FDA alignment on the RESTORE study parameters for chronic tetraplegia, ongoing CONNECT SCI biomechanical gait analyses, and plans to initiate the RESTORE study in mid-2026. The company listed on Nasdaq under 'NGEN' and strengthened its leadership team with key senior appointments. Financially, NervGen ended Q1 2026 with $16.6M in cash and investments, increased ...
05-18 11:15
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Buy rating and announces Price Target of $18.
04-27 19:38
NervGen Pharma Appoints Keith Vendola CFO, Effective Immediately
NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic
04-27 19:37
NervGen Pharma Completes End-Of-Phase 2 Meeting With FDA, Restores Phase 3 Registrational Trial To Evaluate NVG-291 To Treat Chronic Tetraplegia
NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and
04-07 19:32
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
NervGen Pharma reported positive updates on its NVG-291 drug candidate for chronic tetraplegia, including successful Phase 1b/2a results, significant functional improvements, and plans for a Phase 3 study in mid-2026. The company also expects to expand NVG-291 into additional clinical indications and strengthen its leadership team to support its growth. Financially, the company had $22.1M in cash as of December 2025 and continued to advance its n...
03-31 11:45
NervGen Pharma Voluntarily Delisting From TSX Venture Exchange, Effective March 16
NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other
03-13 04:28
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
NervGen Pharma Corp. has voluntarily delisted its common shares from the TSX Venture Exchange, effective March 16, 2026, to reduce costs and administrative burdens. The company will continue trading on Nasdaq under the symbol "NGEN," with no action required by shareholders. This decision aligns with NervGen’s strategic focus on advancing its lead therapeutic candidate, NVG-291, in late-stage development for spinal cord injury treatment.
03-12 20:15
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President of Patient Advocacy and Clinical Affairs. Both bring extensive experience to support NervGen's lead therapeutic, NVG-291, which is advancing through clinical trials for spinal cord injury (SCI). Ruff, with over 30 years in regulatory affairs, will oversee the company's regulatory strategy, while McSherry will ensure p...
03-04 12:30
NervGen Pharma to Participate at Upcoming Investor Conferences
NervGen Pharma Corp., a biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury (SCI) and neurologic conditions, announced that its executives will participate in upcoming investor conferences: the Oppenheimer 36th Annual Healthcare conference on February 25th, TD Cowen’s 46th Annual Health Care conference on March 2nd, and the Leerink Partners Global Healthcare conference on March 8th-11th. The company’s lead can...
02-18 12:30
